Sinphar Pharmaceutical Co.,Ltd. (1734.TW)
TWD 30.9
(0.65%)
TWD 30.9
(0.65%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.85 Billion TWD | -3.88% |
| 2022 | 2.96 Billion TWD | -5.58% |
| 2021 | 3.14 Billion TWD | 5.39% |
| 2020 | 2.98 Billion TWD | 9.93% |
| 2019 | 2.71 Billion TWD | 10.52% |
| 2018 | 2.45 Billion TWD | 1.61% |
| 2017 | 2.41 Billion TWD | -0.33% |
| 2016 | 2.42 Billion TWD | -0.08% |
| 2015 | 2.42 Billion TWD | 1.71% |
| 2014 | 2.38 Billion TWD | 7.96% |
| 2013 | 2.2 Billion TWD | 21.02% |
| 2012 | 1.82 Billion TWD | -6.95% |
| 2011 | 1.96 Billion TWD | 26.39% |
| 2010 | 1.55 Billion TWD | 4.13% |
| 2009 | 1.49 Billion TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.98 Billion TWD | 6.02% |
| 2024 Q1 | 2.81 Billion TWD | -1.17% |
| 2023 FY | 2.85 Billion TWD | -3.88% |
| 2023 Q4 | 2.85 Billion TWD | -1.41% |
| 2023 Q3 | 2.89 Billion TWD | 3.93% |
| 2023 Q1 | 2.67 Billion TWD | -9.75% |
| 2023 Q2 | 2.78 Billion TWD | 3.94% |
| 2022 Q3 | 2.89 Billion TWD | -4.71% |
| 2022 Q1 | 3.19 Billion TWD | 1.72% |
| 2022 FY | 2.96 Billion TWD | -5.58% |
| 2022 Q4 | 2.96 Billion TWD | 2.57% |
| 2022 Q2 | 3.03 Billion TWD | -5.03% |
| 2021 Q1 | 3.27 Billion TWD | 9.88% |
| 2021 Q4 | 3.14 Billion TWD | 2.11% |
| 2021 FY | 3.14 Billion TWD | 5.39% |
| 2021 Q3 | 3.07 Billion TWD | -0.53% |
| 2021 Q2 | 3.09 Billion TWD | -5.58% |
| 2020 Q3 | 3.02 Billion TWD | -3.79% |
| 2020 FY | 2.98 Billion TWD | 9.93% |
| 2020 Q4 | 2.98 Billion TWD | -1.37% |
| 2020 Q1 | 3 Billion TWD | 10.72% |
| 2020 Q2 | 3.14 Billion TWD | 4.63% |
| 2019 Q2 | 2.91 Billion TWD | 17.42% |
| 2019 FY | 2.71 Billion TWD | 10.52% |
| 2019 Q4 | 2.71 Billion TWD | -3.46% |
| 2019 Q3 | 2.81 Billion TWD | -3.58% |
| 2019 Q1 | 2.48 Billion TWD | 1.12% |
| 2018 Q4 | 2.45 Billion TWD | -0.1% |
| 2018 Q1 | 2.39 Billion TWD | -0.83% |
| 2018 Q2 | 2.51 Billion TWD | 4.93% |
| 2018 FY | 2.45 Billion TWD | 1.61% |
| 2018 Q3 | 2.45 Billion TWD | -2.26% |
| 2017 Q4 | 2.41 Billion TWD | 3.15% |
| 2017 FY | 2.41 Billion TWD | -0.33% |
| 2017 Q2 | 2.32 Billion TWD | 1.49% |
| 2017 Q3 | 2.34 Billion TWD | 0.71% |
| 2017 Q1 | 2.29 Billion TWD | -5.46% |
| 2016 Q1 | 2.33 Billion TWD | -3.94% |
| 2016 Q4 | 2.42 Billion TWD | -6.61% |
| 2016 Q2 | 2.5 Billion TWD | 7.31% |
| 2016 Q3 | 2.59 Billion TWD | 3.79% |
| 2016 FY | 2.42 Billion TWD | -0.08% |
| 2015 Q4 | 2.42 Billion TWD | 10.91% |
| 2015 Q3 | 2.18 Billion TWD | -6.78% |
| 2015 Q1 | 2.21 Billion TWD | -7.03% |
| 2015 Q2 | 2.34 Billion TWD | 5.81% |
| 2015 FY | 2.42 Billion TWD | 1.71% |
| 2014 Q2 | 2.28 Billion TWD | 7.23% |
| 2014 Q3 | 2.17 Billion TWD | -4.79% |
| 2014 FY | 2.38 Billion TWD | 7.96% |
| 2014 Q4 | 2.38 Billion TWD | 9.43% |
| 2014 Q1 | 2.13 Billion TWD | -3.37% |
| 2013 Q4 | 2.2 Billion TWD | 11.02% |
| 2013 FY | 2.2 Billion TWD | 21.02% |
| 2013 Q2 | 1.95 Billion TWD | 6.15% |
| 2013 Q1 | 1.83 Billion TWD | 0.71% |
| 2013 Q3 | 1.99 Billion TWD | 1.97% |
| 2012 Q2 | 1.61 Billion TWD | 9.33% |
| 2012 FY | 1.82 Billion TWD | -6.95% |
| 2012 Q1 | 1.47 Billion TWD | -24.82% |
| 2012 Q3 | 1.74 Billion TWD | 8.33% |
| 2012 Q4 | 1.82 Billion TWD | 4.51% |
| 2011 Q4 | 1.96 Billion TWD | 31.6% |
| 2011 Q1 | 1.56 Billion TWD | 0.67% |
| 2011 Q2 | 1.56 Billion TWD | 0.03% |
| 2011 FY | 1.96 Billion TWD | 26.39% |
| 2011 Q3 | 1.49 Billion TWD | -4.62% |
| 2010 Q4 | 1.55 Billion TWD | 0.0% |
| 2010 FY | 1.55 Billion TWD | 4.13% |
| 2009 FY | 1.49 Billion TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Apex Biotechnology Corp. | 500.07 Million TWD | -470.562% |
| Panion & Bf Biotech Inc. | 1.32 Billion TWD | -115.483% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 1.82 Billion TWD | -56.648% |
| GenMont Biotech Incorporation | 204.05 Million TWD | -1298.226% |
| Abnova (Taiwan) Corporation | 69.42 Million TWD | -4009.828% |
| Adimmune Corporation | 3.7 Billion TWD | 23.029% |
| Tanvex BioPharma, Inc. | 1.94 Billion TWD | -46.899% |
| Polaris Group | 1.46 Billion TWD | -94.787% |
| Energenesis Biomedical CO.,LTD. | 24.58 Million TWD | -11504.535% |
| UnicoCell Biomed Co., Ltd. | 89.48 Million TWD | -3088.404% |
| PELL Bio-Med Technology Co. Ltd. | 236.76 Million TWD | -1105.08% |